Intellipharmaceutics International Inc.
featured news
May 6, 2022
News
Wayland Group Corp. (f/k/a, Maricann): Quebec Court Quick to Protect Québécois Investors
(May 5, 2022) Wayland Group Corp., (“WAYL”) filed papers seeking bankruptcy protection and it was liquidated by selling assets for pennies on the dollar ~ and back to the same sellers! Investors lost. The Court approved and issued a “Stay of Litigation” so that investors could not advance their claims […]
November 5, 2021
News
Ontario Division Court unanimously agrees to allow investors’ claims to advance against Auxly Cannabis Group, Inc.
(November 2, 2021) The Ontario Superior Court of Justice – Divisional Court (Justices Swinton, Sachs, and Favreau), 2021 ONSC 7117, have allowed the investor claims against Auxly Cannabis Group, Inc. to proceed forward into discovery and trial by denying the appeal of Justice Morgan’s straight-forward (tell-it-how-it-is) decision granting investors leave […]
July 30, 2021
News
U.S. Securities and Exchange Commission Warns Investors investing in China-based companies
(July 30, 2021) The U.S. Securities and Exchange Commission (“SEC”) has identified a number of China-based companies raising capital through offshore shell companies. In a number sectors in China, companies are not allowed to have foreign ownership and cannot directly list on stock exchanges outside of China. Some of these […]
June 25, 2021
News
Intellipharmaceutics International, Inc., Shareholder Class Certification and Settlement
(June 25, 2021) The Ontario Superior Court of Justice (Justice Morgan) certified a Class of investors that purchased Intellipharmaceutics International, Inc.’s securities (“IPCI”) listed on the Toronto Stock Exchange and scheduled a hearing date to approve a Settlement Agreement between investors and IPCI. The Plaintiffs allege that Intellipharm’s value and […]
June 16, 2021
Corporate
Auxly Cannabis Group Inc., Investors allowed to proceed into discovery
(June 16, 2021) The Ontario Superior Court of Justice has granted investors’ motion to allow them to proceed into discovery finding that there is a reasonable possibility that Auxly (“XLY”) released its 3Q 2018 MD&A with misrepresentations about its relationship with FSD Pharma Inc., (“HUGE”) and the status of the […]
schedule a free consultation
$200M+
In Canadian Settlements
Top 50
ISS SCAS Top 50 (2017-2021)
10+
Years Representing Canadian Investors
12+
Canadian Court Decisions Advancing Investors’ Rights
On the Cutting Edge of the Profession
Legal Intelligencer
53
Years
